NRAS mutations are rare in colorectal cancer

Diagnostic Molecular Pathology

Volumn 19, Issue 3, 2010, Pages 157-163

  Irahara, Natsumi ^a   Baba, Yoshifumi ^a   Nosho, Katsuhiko ^a   Shima, Kaori ^a   Yan, Liying ^d   Dias Santagata, Dora ^b   Iafrate, Anthony John ^b   Fuchs, Charles S ^a,c   Haigis, Kevin M ^b   Ogino, Shuji ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d EpigenDx   (United States)

Author keywords

clinical outcome; colon cancer; NRAS; sequencing; signal transduction

Indexed keywords

ASPARAGINASE; B RAF KINASE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CANCER; CPG ISLAND; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; NRAS GENE; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PYROSEQUENCING; RARE DISEASE; TUMOR GENE;

AGED; COHORT STUDIES; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA-CYTOSINE METHYLASES; FEMALE; GENES, RAS; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; PATHOLOGY, MOLECULAR; PHOSPHATIDYLINOSITOL 3-KINASES; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; SEQUENCE ANALYSIS, DNA;

EID: 77956238031     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/PDM.0b013e3181c93fd1     Document Type: Article

References (52)

1. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3:459-465.
2. Diaz-Flores E, Shannon K. Targeting oncogenic Ras. Genes Dev. 2007;21:1989-1992.
3. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7:295-308.
4. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11-22.
5. Nosho K, Kawasaki T, Ohnishi M, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia. 2008;10:534-541.
6. Ogino S, Nosho K, Kirkner GJ, et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol. 2009;27:1477-1484.
7. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-4689.
8. Omholt K, Platz A, Kanter L, et al. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res. 2003;9:6483-6488.
9. Houben R, Becker JC, Kappel A, et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog. 2004;3:6.
10. Ugurel S, Thirumaran RK, Bloethner S, et al. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One. 2007;2:e236.
11. Banerji U, Affolter A, Judson I, et al. BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther. 2008;7:737-739.
12. Dhomen N, Marais R. New insight into BRAF mutations in cancer. Curr Opin Genet Dev. 2007;17:31-39.
13. Ollikainen M, Gylling A, Puputti M, et al. Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int J Cancer. 2007;121:915-920.
14. Rossi DJ, Weissman IL. Pten, tumorigenesis, and stem cell self-renewal. Cell. 2006;125:229-231.
15. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005;7:561-573.
16. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116:855-867.
17. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci\USA. 2008;105: 2652-2657.
18. Nosho K, Irahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE. 2008;3:e3698.
19. Velho S, Oliveira C, Ferreira A, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer. 2005;41: 1649-1654.
20. Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst. 2006;98:451-459.
21. Colditz GA, Hankinson SE. The nurses' health study: lifestyle and health among women. Nat Rev Cancer. 2005;5:388-396.
22. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007; 356:2131-2142.
23. Ogino S, Kawasaki T, Kirkner GJ, et al. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn. 2007;9:305-314.
24. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn. 2005;7:413-421.
25. Dietmaier W, Hartmann A, Wallinger S, et al. Multiple mutation analyses in single tumor cells with improved whole genome amplification. Am J Pathol. 1999;154:83-95.
26. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248-5257.
27. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000;28:E32.
28. Ogino S, Kawasaki T, Kirkner GJ, et al. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn. 2006; 8:582-588.
29. Ogino S, Cantor M, Kawasaki T, et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut. 2006;55:1000-1006.
30. Ogino S, Kawasaki T, Kirkner GJ, et al. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. BMC Cancer. 2007;7:72.
31. Ogino S, Kawasaki T, Brahmandam M, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn. 2006;8:209-217.
32. Ogino S, Kawasaki T, Nosho K, et al. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer. 2008;122: 2767-2773.
33. Nosho K, Kawasaki T, Chan AT, et al. Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype. Histopathology. 2008; 53:588-598.
34. Kawasaki T, Nosho K, Ohnishi M, et al. Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Neoplasia. 2007; 9:569-577.
35. Ogino S, Meyerhardt JA, Cantor M, et al. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res. 2005;11:6650-6656.
36. Ogino S, Brahmandam M, Cantor M, et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol. 2006;19:59-68.
37. Barault L, Veyrie N, Jooste V, et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer. 2008;122:2255-2259.
38. Kearney KE, Pretlow TG, Pretlow TP. Increased expression of fatty acid synthase in human aberrant crypt foci: possible target for colorectal cancer prevention. Int J Cancer. 2009;125:249-252.
39. Ogino S, Nosho K, Irahara N, et al. A cohort study of cyclin d1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res. 2009;15:4431-4438.
40. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;58:90-96.
41. Ogino S, Shima K, Nosho K, et al. A cohort study of p27 localization in colon cancer, body mass index, and patient survival. Cancer Epidemiol Biomarkers Prev. 2009;18:1849-1858.
42. Jaiswal BS, Janakiraman V, Kljavin NM, et al. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One. 2009;4:e5717.
43. Lea IA, Jackson MA, Dunnick JK. Genetic pathways to colorectal cancer. Mutat Res. 2009;670:96-98.
44. Quinlan MP, Settleman J. Isoform-specific ras functions in development and cancer. Future Oncol. 2009;5:105-116.
45. Oudejans JJ, Slebos RJ, Zoetmulder FA, et al. Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer. 1991;49: 875-879.
46. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319: 525-532.
47. Parikh C, Ren R. Mouse model for NRAS-induced leukemogenesis. Methods Enzymol. 2008;439:15-24.
48. Parikh C, Subrahmanyam R, Ren R. Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice. Cancer Res. 2007;67:7139-7146.
49. Campbell SL, Khosravi-Far R, Rossman KL, et al. Increasing complexity of Ras signaling. Oncogene. 1998;17:1395-1413.
50. Demunter A, Stas M, Degreef H, et al. Analysis of N-and K-ras mutations in the distinctive tumor progression phases of melanoma. J Invest Dermatol. 2001;117:1483-1489.
51. Haigis KM, Kendall KR, Wang Y, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet. 2008;40:600-608.
52. Yun J, Rago C, Cheong I, et al. Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells. Science. 2009;325:1555-1559.